Baricitinib-associated events were more frequently categorized under general disorders, infections, and laboratory investigations, consistent with known pharmacologic effects of JAK1/JAK2 inhibition and echoed by findings in both clinical trials and real-world studies (6, 7). The gene discussed is JAK1; the disease is infection.